1.2734
price up icon16.36%   0.2034
 
loading
Schlusskurs vom Vortag:
$1.07
Offen:
$1.07
24-Stunden-Volumen:
2.36M
Relative Volume:
0.99
Marktkapitalisierung:
$142.71M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.7718
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+16.36%
1M Leistung:
+12.16%
6M Leistung:
-42.89%
1J Leistung:
-68.08%
1-Tages-Spanne:
Value
$1.07
$1.25
1-Wochen-Bereich:
Value
$0.9301
$1.25
52-Wochen-Spanne:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Firmenname
Fate Therapeutics Inc
Name
Telefon
858.875.1803
Name
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
181
Name
Twitter
@fatethx
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
FATE's Discussions on Twitter

Vergleichen Sie FATE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FATE
Fate Therapeutics Inc
1.245 122.66M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
ONC
Beigene Ltd Adr
232.89 25.21B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.28 112.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2409 40.72M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
594.37 62.15B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
71.35 5.75B 0 -153.72M -103.81M -2.00

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-18 Hochstufung BofA Securities Underperform → Neutral
2024-06-17 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-24 Herabstufung H.C. Wainwright Buy → Neutral
2023-01-06 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2023-01-06 Herabstufung Cowen Outperform → Market Perform
2023-01-06 Herabstufung Piper Sandler Overweight → Neutral
2023-01-06 Herabstufung Stifel Buy → Hold
2023-01-06 Herabstufung Truist Buy → Hold
2023-01-06 Herabstufung Wedbush Outperform → Neutral
2023-01-03 Herabstufung Guggenheim Buy → Neutral
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-12-15 Eingeleitet Goldman Sell
2022-11-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-10-10 Eingeleitet Canaccord Genuity Buy
2022-08-18 Fortgesetzt Wells Fargo Overweight
2022-07-28 Eingeleitet Needham Hold
2022-07-11 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-06-03 Eingeleitet Robert W. Baird Neutral
2022-02-11 Fortgesetzt BMO Capital Markets Market Perform
2021-12-15 Hochstufung Wedbush Neutral → Outperform
2021-12-07 Eingeleitet Cowen Outperform
2021-11-09 Hochstufung Citigroup Neutral → Buy
2021-08-26 Eingeleitet Morgan Stanley Equal-Weight
2021-06-07 Hochstufung H.C. Wainwright Neutral → Buy
2021-05-07 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Jefferies Buy
2021-02-26 Eingeleitet BofA Securities Buy
2021-02-26 Herabstufung Wedbush Outperform → Neutral
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-27 Fortgesetzt H.C. Wainwright Neutral
2020-05-13 Eingeleitet H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-01-09 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-12-30 Bestätigt Mizuho Buy
2019-12-09 Hochstufung Wells Fargo Market Perform → Outperform
2019-11-12 Eingeleitet SunTrust Buy
2019-11-06 Herabstufung Wells Fargo Outperform → Market Perform
2019-10-01 Eingeleitet Stifel Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-07-22 Eingeleitet Cantor Fitzgerald Overweight
2019-07-12 Eingeleitet Oppenheimer Outperform
2019-06-13 Eingeleitet Mizuho Buy
2019-06-07 Eingeleitet ROTH Capital Neutral
2019-05-31 Eingeleitet Guggenheim Buy
2019-05-24 Fortgesetzt Citigroup Buy
2019-03-28 Eingeleitet SVB Leerink Outperform
2019-01-03 Herabstufung Stephens Overweight → Equal-Weight
2018-11-05 Eingeleitet Jefferies Buy
2018-08-01 Eingeleitet Citigroup Buy
2018-03-06 Herabstufung H.C. Wainwright Buy → Neutral
Alle ansehen

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

pulisher
03:46 AM

Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

03:46 AM
pulisher
May 17, 2025

StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World

May 17, 2025
pulisher
May 17, 2025

Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World

May 17, 2025
pulisher
May 17, 2025

Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World

May 17, 2025
pulisher
May 17, 2025

What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World

May 17, 2025
pulisher
May 16, 2025

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN

May 16, 2025
pulisher
May 16, 2025

Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

May 16, 2025
pulisher
May 15, 2025

Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus

May 15, 2025
pulisher
May 14, 2025

FATE Stock Update: Analyst Lowers Price Target, Maintains Neutra - GuruFocus

May 14, 2025
pulisher
May 14, 2025

4 Analysts Assess Fate Therapeutics: What You Need To Know - Benzinga

May 14, 2025
pulisher
May 14, 2025

Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Resu - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Ce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Fate Therapeutics: Q1 Earnings Snapshot - CT Insider

May 14, 2025
pulisher
May 14, 2025

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 13, 2025

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times

May 13, 2025
pulisher
May 13, 2025

FATE THERAPEUTICS INC SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

What Is Going On With Fate Therapeutics Inc (NASDAQ: FATE)? - Stocksregister

May 13, 2025
pulisher
May 13, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP - Defense World

May 13, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 12, 2025
pulisher
May 11, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by MetLife Investment Management LLC - Defense World

May 11, 2025
pulisher
May 10, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN - Defense World

May 10, 2025
pulisher
May 08, 2025

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha

May 08, 2025
pulisher
May 07, 2025

Fate Therapeutics Inc (NASDAQ: FATE) Drops -18.14 Percent In Recent Trading, What Questions Do You Have? - Stocksregister

May 07, 2025
pulisher
May 05, 2025

Fate Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 02, 2025
pulisher
May 02, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages - Defense World

May 02, 2025
pulisher
May 01, 2025

Fate Therapeutics Inc [FATE] Records 50-Day SMA of $1.0480 - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

LPL Financial LLC Buys New Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Uncovering the Potential of Fate Therapeutics Inc (FATE) Stock - investchronicle.com

Apr 30, 2025
pulisher
Apr 30, 2025

There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Fate Therapeutics to Present Clinical and Preclinical Data at ASGCT 28th Annual Meeting - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Was anything negative for Fate Therapeutics Inc (FATE) stock last session? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Fate Therapeutics Announces Five Presentations on - GlobeNewswire

Apr 29, 2025
pulisher
Apr 28, 2025

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo

Apr 27, 2025
pulisher
Apr 26, 2025

Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

FATE Shares Experience Decline in Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com

Apr 21, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 17, 2025

Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.28
price down icon 0.78%
$572.34
price up icon 1.14%
$3.8565
price down icon 0.51%
$32.58
price up icon 4.88%
$290.85
price up icon 1.76%
$70.88
price down icon 0.56%
Kapitalisierung:     |  Volumen (24h):